Excalibur Pathology is an ophthalmic histology service with nearly 50 years of experience. Our special fixative prevents retinal detachment in paraffin sections and enhances IHC and RNAScope staining. We have done eyes from mice that have been to space!
Eurofins Medical Device Testing
With extensive knowledge of the commercialization process, regulatory requirements and scientific trends in the Industry, Eurofins Medical Device Testing offers regulatory compliance expertise and experienced GMP/GLP/ISO 17025 testing to ensure rapid turnaround times with the highest level of service and most advanced technologies for your analytical chemical, microbiological, biocompatibility, electrical, mechanical and package testing needs. Our scientists and engineers have been assisting companies, large and small, with developmental testing for more than 40 years; and our global network of >20 laboratories in North America, Europe and Asia Pacific provide extensive capacity and the highest level of instrument technology with a full scope of testing services. | Eurofins Medical Device Services, with its network of 20+ laboratories around the globe, provides world class medical device consulting, testing, and sterile packaging (design, manufacturing, sterilization, and testing) to GMP/GLP/ISO 17025 standards. With a 40+ year reputation of client service excellence through industry-leading turnaround times, advanced technologies, and regulatory rigor, medical device developers and manufacturers trust Eurofins for at all phases. | With extensive knowledge of the commercialization process, regulatory requirements and scientific trends in the Industry, Eurofins Medical Device Testing offers regulatory compliance expertise and experienced GMP/GLP/ISO 17025 testing to ensure rapid turnaround times with the highest level of service and most advanced technologies for your analytical chemical, microbiological, biocompatibility, mechanical and package testing needs. Our scientists and engineers have been assisting companies, large and small, with developmental testing for more than 40 years; and our global network of >20 laboratories in North America, Europe and Asia Pacific provide extensive capacity and the highest level of instrument technology with a full scope of testing services. | From implants and instruments, to single-use and combination products, as well as active electronic devices, Eurofins Medical Device Services network of laboratories provides the optimal testing strategy for all types of class I, II and III medical devices and are dedicated to helping you verify and validate your product designs; confirm safety and efficacy; and ensure user needs are met. With extensive knowledge of the commercialization process, medical device preclinical testing, international regulatory requirements, and scientific trends, our scientists and engineers have been assisting companies, large and small, with developmental testing and regulatory submissions for more than 40 years. Our >20 state-of-the-art medical device services facilities throughout North America, Europe and Asia Pacific offer extensive capacity and the highest level of instrument technology, enabling us to provide the full scope of testing services required by the Medical Device Industry, including Analytical Chemistry, Microbiology, Biocompatibility, Electrical & Mechanical, Packaging and Stability Testing & Storage. With an unwavering commitment to global regulatory standards, Eurofins Medical Device Services network of laboratories can help develop and execute all types of medical device testing plans, and navigate the regulatory pathway to market anywhere in the world. We maintain quality systems compliant with cGMP, GLP and ISO 17025, and conduct testing in accordance with ISO, ASTM, ANSI, AAMI standards, as well as custom test methodologies to meet our customers’ unique challenges. Eurofins Medical Device Services is a brand used by several distinct legal entities, across a global network of more than 20 laboratories across North America, Europe and Asia Pacific.
Encompass Pharmaceutical Services, Inc.
Encompass Ophthalmic Development Services, Inc. offers a full range of ophthalmic development and formulation services from pre-formulation through manufacturing scale-up. • Preclinical Support • Consulting • Ophthalmic Drug Formulation • Ophthalmic Drug Delivery • Ex-vivo drug release characterization • Analytical Method Development and Validation • Pre-Clinical Supplies Manufacturing • Manufacturing Process Development, Scale-up, and Validation • GMP Stability Studies • Clinical Supplies and Manufacturing Support
Cyagen Biomodels LLC
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and advanced CRO solutions for biomedical research and drug development. With more than 900 employees and research facilities covering 40,000 m², Cyagen supports researchers in over 100 countries and has contributed to more than 13,000 peer-reviewed publications, including in Cell, Nature, and Science. Headquartered in Santa Clara, California, Cyagen also operates subsidiaries in Japan and China, with major R&D and production centers in Guangzhou, Suzhou, and Gu’an. Combining expertise in cell and animal model generation with AI-driven discovery platforms, Cyagen provides scalable, reliable, one-stop solutions for basic research and preclinical drug development. Cyagen has developed several proprietary platforms to advance translational research, including HUGO-GT™ genomic humanized mouse models, the Rare Disease Data Center (RDDC) integrating genetic databases and AI tools
China Eye Valley
China Eye Valley is a national-level ophthalmic innovation ecosystem based in Wenzhou, China, integrating research, clinical care, industry, and investment. Anchored by the Wenzhou Medical University Eye Hospital, it supports the full pipeline from basic research to commercialization. The platform hosts over 400 eye health enterprises and offers advanced capabilities in biomaterials, medical devices, AI-driven diagnostics, and real-world evidence (RWE) studies. At ARVO, China Eye Valley showcases its collaborative model and seeks global partnerships to accelerate innovation, regulatory advancement, and market access in ophthalmology.
Charles River
Charles River is a global preclinical oncology CRO delivering end to end oncology and immuno oncology drug discovery, from target identification and validation through IND enabling and clinical. We partner with academic, biotechnology, and pharmaceutical companies to advance innovative cancer therapies. In 2025, Charles River supported 87% of FDA-approved oncology therapies, including first-in-class and best-in-class drugs. Our capabilities span small molecules, biologics, antibodies, antibody drug conjugates (ADCs), immunotherapies, checkpoint inhibitors, cell therapies, and gene therapies. Our research model (RMS) portfolio includes immunodeficient mice and rats, PBMC and CD34+ humanized mouse models, end-to-end support from colony management for Genetically Engineered Model (GEM), including transgenic model generation and breeding, to vivarium rental or customizable onsite services (staffing, consulting, training), and CRADL® support in global biohubs. Our oncology platforms include 1,700+ xenograft models (PDX, CDX, syngeneic, humanized), covering 45+ cancer indications across solid tumors, hematologic, and pediatric cancers. Integrated in vitro, ex vivo, NAMs and 3D tumor models—including organoids, tumoroids, and tissue microarrays (TMAs)- support efficacy, PK/PD, biomarker, and translational decision making. Multi omics, AI enabled analytics, and strategic CMC/CDMO capabilities help teams plan manufacturing earlier, strengthen regulatory readiness, improve study design, reduce risk, and accelerate candidate to patients. Learn more at criver.com/cancer-research-annual-meeting-2026 | Charles River has supported researchers in advancing ocular therapies for more than two decades, with a comprehensive suite of capabilities designed to meet your program needs. We help you progress small molecules, biologics, gene and cell therapies, and implantable devices from concept to clinic with confidence. Our team provides rigorous efficacy, distribution, and safety assessments supported by state-of-the-art imaging, functional evaluations, and New Approach Methodologies (NAMs) to help you improve predictability and generate high-quality data for global regulatory submissions. We also assess the ocular effects of systemic compounds for non-ocular indications, helping you refine study design, manage timelines and resources, and reduce animal use. We are committed to partnering with you at every stage to help bring meaningful treatments to patients worldwide because every moment matters. | Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com. | Charles River is committed to helping companies like yours get your product to market safely and efficiently. Whether you’re still in development or already manufacturing, our Safety Assessment and Microbial Solutions services provide state-of-the-art technology and expert regulatory advice that will help you anticipate challenges, avoid roadblocks, and make better decisions.
BioSpherix, LLC
BioSpherix stands at the forefront of advanced cell and tissue culture technology, dedicated to providing Cytocentric® environments designed for optimal cell care. Our flagship product, the Xvivo System, exemplifies this commitment. By harnessing our proprietary closed-system technology, the Xvivo System revolutionizes cell science and is expertly tailored to meet the demands of your GMP or R&D protocols. This modular and cost-effective system features patented self-sterilizing technology, offering a superior alternative to traditional open systems that expose cell and tissue cultures to unpredictable and non-physiologic conditions. The Xvivo System enhances operational efficiency, adapts to your evolving needs, minimizes contamination risks, and ultimately cultivates healthier, more robust cells. At BioSpherix, our philosophy is Cytocentric®: prioritizing the needs of cells above all else.
Altasciences
Altasciences is an integrated drug development organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.